Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.57 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.57 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27080119 | 0.98 | GNAI3 (0.59) | GNAI3GNAO1GNAI1NPC1CACNA1B | |
| SCHEMBL14294406 | 0.90 | GNAI3 (0.51) | GNAI3GNAO1GNAI1NPC1CACNA1B | |
| SCHEMBL6586631 | 0.88 | GNAI3 (0.47) | GNAI3GNAO1GNAI1NPC1CACNA1B | |
| SCHEMBL12385904 | 0.84 | NPC1 (0.67) | NPC1POLBDRD2DRD3ALDH1A1 | |
| SCHEMBL3861156 | 0.83 | GAA (0.54) | POLBALDH1A1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL584259 | 0.81 | GNAI3 (0.51) | GNAI3GNAO1GNAI1NPC1CACNA1B | |
| SCHEMBL7875482 | 0.81 | GNAI3 (0.59) | GNAI3GNAO1GNAI1NPC1CACNA1B | |
| SCHEMBL12436979 | 0.81 | ALDH1A1 (0.47) | NPC1POLBDRD2DRD3ALDH1A1 | |
| SCHEMBL15431605 | 0.81 | ALDH1A1 (0.47) | GNAI3GNAO1GNAI1NPC1POLB | |
| SCHEMBL16826909 | 0.80 | NAMPT (0.46) | GNAI3GNAO1GNAI1NPC1CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140044672-A1 | CONJUGATES OF A GM-CSF MOIETY AND A POLYMER | NEKTAR THERAPEUTICS (US) | 2014-02-13 | — | — | US | disclosed |
| US-8591943-B2 | Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-26 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| EP-2417138-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | Schering Corporation (US) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010118207-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010118207-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140044672-A1 | CONJUGATES OF A GM-CSF MOIETY AND A POLYMER | CSF3R, GMFG, CSF1R | GNAI3 1465/4885GNAO1 1969/4885GNAI1 1425/4885 |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | GNAI3 847/4885GNAO1 1000/4885GNAI1 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.